Association between somatic symptom disorder and symptoms with daily life impairment after SARS-CoV-2 infection - results from a population-based cross-sectional study.
Concentration impairment
Dyspnea
Fatigue
Post-Covid syndrome
SARS-CoV-2
Somatic symptom disorder
Journal
Journal of psychosomatic research
ISSN: 1879-1360
Titre abrégé: J Psychosom Res
Pays: England
ID NLM: 0376333
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
25
01
2023
revised:
27
02
2023
accepted:
09
03
2023
medline:
18
4
2023
pubmed:
19
3
2023
entrez:
18
3
2023
Statut:
ppublish
Résumé
Post-COVID syndrome (PCS) is defined by symptom persistence accompanied by daily life impairment (DLI). The association of somatic symptom disorder (SSD) and symptoms with DLI after SARS-CoV-2 infection in the general population is unclear to date. The main objective of the study was to investigate the association of possible SSD, depression, anxiety, and participant-reported symptoms with DLI in a local population sample. Anonymised cross-sectional study. A symptom questionnaire, including the scales Patient Health Questionnaire PHQ-15 (somatisation module), SSD-12 (psychological distress in SSD), PHQ-2 (depression), GAD-2 (anxiety), and FAS (fatigue assessment scale) was sent in 02/2022 to all adult residents of the district Bad Tölz-Wolfratshausen, Germany, who were registered for SARS-CoV-2-infection between 03/2020 and 11/2021 (8925 delivered). Associations between DLI, symptoms and scales were estimated using binary logistic regression models and network analysis. 2828 questionnaires (31.7%) were complete. 1486 (52.5%) reported persistent symptoms, and 509 (18.0%) perceived DLI. DLI was strongest associated with self-reported fatigue (OR 7.86; 95%CI 5.63-10.97), dyspnea (3.93; 2.73-5.67), impaired concentration (3.05; 2.17-4.30), SSD-12 (4.36; 2.57-7.41), and PHQ-2 (2.48; 1.57-3.92). Self-reported fatigue showed the strongest correlation (r PCS appears as a complex clinical picture in which SSD might play an important role when DLI is present. The pychological burden might partly be explained by the persistent symptoms, which are difficult to treat up to now. Screening for SSD could help in differential diagnostic decision-making to ensure that patients receive appropriate psychosocial interventions for disease coping.
Sections du résumé
BACKGROUND
Post-COVID syndrome (PCS) is defined by symptom persistence accompanied by daily life impairment (DLI). The association of somatic symptom disorder (SSD) and symptoms with DLI after SARS-CoV-2 infection in the general population is unclear to date. The main objective of the study was to investigate the association of possible SSD, depression, anxiety, and participant-reported symptoms with DLI in a local population sample.
METHODS
Anonymised cross-sectional study. A symptom questionnaire, including the scales Patient Health Questionnaire PHQ-15 (somatisation module), SSD-12 (psychological distress in SSD), PHQ-2 (depression), GAD-2 (anxiety), and FAS (fatigue assessment scale) was sent in 02/2022 to all adult residents of the district Bad Tölz-Wolfratshausen, Germany, who were registered for SARS-CoV-2-infection between 03/2020 and 11/2021 (8925 delivered). Associations between DLI, symptoms and scales were estimated using binary logistic regression models and network analysis.
RESULTS
2828 questionnaires (31.7%) were complete. 1486 (52.5%) reported persistent symptoms, and 509 (18.0%) perceived DLI. DLI was strongest associated with self-reported fatigue (OR 7.86; 95%CI 5.63-10.97), dyspnea (3.93; 2.73-5.67), impaired concentration (3.05; 2.17-4.30), SSD-12 (4.36; 2.57-7.41), and PHQ-2 (2.48; 1.57-3.92). Self-reported fatigue showed the strongest correlation (r
CONCLUSION
PCS appears as a complex clinical picture in which SSD might play an important role when DLI is present. The pychological burden might partly be explained by the persistent symptoms, which are difficult to treat up to now. Screening for SSD could help in differential diagnostic decision-making to ensure that patients receive appropriate psychosocial interventions for disease coping.
Identifiants
pubmed: 36933364
pii: S0022-3999(23)00087-9
doi: 10.1016/j.jpsychores.2023.111230
pmc: PMC10010058
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111230Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest There are no conflicts of interest.
Références
Neurol Ther. 2022 Dec;11(4):1637-1657
pubmed: 36028604
Psychol Med. 2022 Mar;52(4):632-648
pubmed: 34776017
J Psychosom Res. 2023 Feb;165:111135
pubmed: 36623391
BMJ. 2013 Mar 18;346:f1580
pubmed: 23511949
Psychol Med. 2020 Jan;50(2):324-333
pubmed: 30729902
BMJ. 2022 Oct 13;379:e071050
pubmed: 36229057
Nat Commun. 2022 Jun 28;13(1):3528
pubmed: 35764621
BMJ Open. 2022 Sep 22;12(9):e064979
pubmed: 36137635
Nat Med. 2022 Mar;28(3):583-590
pubmed: 35132265
Pneumologie. 2021 Nov;75(11):869-900
pubmed: 34474488
BMJ. 2021 Jun 23;373:n1559
pubmed: 34162532
J Neurol Neurosurg Psychiatry. 2022 Aug 25;:
pubmed: 36008115
Br J Health Psychol. 2004 Sep;9(Pt 3):279-91
pubmed: 15296678
EClinicalMedicine. 2022 Jul 18;51:101549
pubmed: 35875815
J Psychosom Res. 2021 Aug;147:110525
pubmed: 34051516
BMJ. 2021 Jul 28;374:n1859
pubmed: 34321219
J Psychosom Res. 2005 Feb;58(2):163-71
pubmed: 15820844
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953
Nature. 2021 Jun;594(7862):259-264
pubmed: 33887749
Nature. 2022 Apr;604(7907):697-707
pubmed: 35255491
Psychosom Med. 2016 Jan;78(1):5-12
pubmed: 26461855
J Psychosom Res. 2023 Jan;164:111084
pubmed: 36436226
Neurogastroenterol Motil. 2022 Feb;34(2):e14187
pubmed: 34060710
J Psychiatr Res. 2021 Dec;144:129-137
pubmed: 34619491
Psychosom Med. 2002 Mar-Apr;64(2):258-66
pubmed: 11914441
J Affect Disord. 2010 Apr;122(1-2):86-95
pubmed: 19616305
BMJ. 2020 Oct 20;371:m3731
pubmed: 33082154
J Psychosom Res. 2003 Apr;54(4):345-52
pubmed: 12670612
J Psychosom Res. 2022 Mar;154:110726
pubmed: 35086054
JAMA. 2022 Oct 25;328(16):1604-1615
pubmed: 36215063
EClinicalMedicine. 2022 Dec 01;55:101762
pubmed: 36474804
Nat Med. 2022 Aug;28(8):1706-1714
pubmed: 35879616
Lancet Psychiatry. 2022 Oct;9(10):815-827
pubmed: 35987197
BMJ. 2021 Jul 26;374:n1648
pubmed: 34312178
Med Care. 2003 Nov;41(11):1284-92
pubmed: 14583691
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937